FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385655145> ?p ?o ?g. }

• W4385655145 endingPage "e990776f" @default.
• W4385655145 startingPage "e990776f" @default.
• W4385655145 abstract "Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: Light-chain (AL) amyloidosis is a rare, progressive, systemic disorder caused by plasma cell dyscrasia (PCD). Amyloid fibrils deposit in organs leading to progressive organ damage and death. Prognosis is poor for patients with cardiac involvement. Median survival is 24 and 4 months for patients in Mayo Stages IIIa and IIIb (based on the 2013 European Modification of the Mayo 2004 staging criteria), respectively. The standard of care (SoC) is anti-PCD therapy to suppress amyloid fibril generation. As yet, there are no therapies that remove deposited fibrils. CAEL-101 is a monoclonal antibody that binds to amyloid fibrils and may facilitate their systemic removal, improve organ function, and increase patient survival. The ongoing trials will evaluate the efficacy and safety of CAEL-101 as a first-in-class treatment to reduce amyloid burden in patients with cardiac AL amyloidosis. Notably, NCT04504825 (Mayo Stage IIIb) is the first randomized, placebo-controlled efficacy clinical trial to formally assess the effects of a pharmacologic agent in this severely ill population. Because the median expected survival for patients in Mayo Stage IIIb is far shorter than for patients in Mayo Stage IIIa (NCT04512235), the sample size required for the former is less than for the latter Aims: The objective of these trials is to evaluate the efficacy and safety of CAEL-101 when administered concurrently with SoC anti-PCD therapy in treatment-naïve patients with cardiac AL amyloidosis in Mayo Stages IIIb or IIIa Methods: These international, multicenter, double-blind, randomized, phase 3 trials, initiated in 2020, are enrolling patients at >100 sites in >20 countries. Newly diagnosed adults with AL amyloidosis Stage IIIb or IIIa measurable hematologic disease, and histopathological diagnosis of amyloidosis with cardiac involvement are eligible. Patients with other forms of amyloidosis, symptomatic orthostatic hypotension, or supine systolic blood pressure <90 mm Hg are ineligible. Patients in Mayo Stages IIIb (N=124; NCT04504825) and IIIa (N=267; NCT04512235) are being randomized 2:1 to receive once-weekly intravenous infusions of CAEL-101 (1000 mg/m2) or placebo for 4 weeks, followed by maintenance dosing every 2 weeks (Figure). In these event-driven studies, treatment will continue to a minimum of 101 and 79 events for 301 and 302, respectively. Patients will receive concurrent institutional SoC anti-PCD therapy at the discretion of the investigator. Overall survival (primary endpoint) will be analyzed via time-to-event log-rank statistics. Secondary endpoints include functional outcomes, quality of life, and echocardiography Results: Summary/Conclusion:Keywords: AL amyloidosis, Treatment, Antibody" @default.
• W4385655145 created "2023-08-09" @default.
• W4385655145 creator A5027145476 @default.
• W4385655145 creator A5065948722 @default.
• W4385655145 creator A5070082694 @default.
• W4385655145 creator A5080444901 @default.
• W4385655145 creator A5085783292 @default.
• W4385655145 creator A5087023542 @default.
• W4385655145 creator A5087195983 @default.
• W4385655145 creator A5091600816 @default.
• W4385655145 date "2023-08-01" @default.
• W4385655145 modified "2023-09-27" @default.
• W4385655145 title "PB2150: CARDIAC AMYLOID REACHING FOR EXTENDED SURVIVAL (CARES) TRIALS: 2 PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED, PHASE 3 TRIALS ASSESSING CAEL-101 IN PATIENTS WITH MAYO STAGES IIIA/IIIB AL AMYLOIDOSIS" @default.
• W4385655145 doi "https://doi.org/10.1097/01.hs9.0000975360.99077.6f" @default.
• W4385655145 hasPublicationYear "2023" @default.
• W4385655145 type Work @default.
• W4385655145 citedByCount "0" @default.
• W4385655145 crossrefType "journal-article" @default.
• W4385655145 hasAuthorship W4385655145A5027145476 @default.
• W4385655145 hasAuthorship W4385655145A5065948722 @default.
• W4385655145 hasAuthorship W4385655145A5070082694 @default.
• W4385655145 hasAuthorship W4385655145A5080444901 @default.
• W4385655145 hasAuthorship W4385655145A5085783292 @default.
• W4385655145 hasAuthorship W4385655145A5087023542 @default.
• W4385655145 hasAuthorship W4385655145A5087195983 @default.
• W4385655145 hasAuthorship W4385655145A5091600816 @default.
• W4385655145 hasBestOaLocation W43856551451 @default.
• W4385655145 hasConcept C126322002 @default.
• W4385655145 hasConcept C141071460 @default.
• W4385655145 hasConcept C142724271 @default.
• W4385655145 hasConcept C159654299 @default.
• W4385655145 hasConcept C203014093 @default.
• W4385655145 hasConcept C2777607188 @default.
• W4385655145 hasConcept C2777633098 @default.
• W4385655145 hasConcept C2779551797 @default.
• W4385655145 hasConcept C2779951007 @default.
• W4385655145 hasConcept C2908647359 @default.
• W4385655145 hasConcept C36394416 @default.
• W4385655145 hasConcept C535046627 @default.
• W4385655145 hasConcept C71924100 @default.
• W4385655145 hasConcept C90924648 @default.
• W4385655145 hasConcept C99454951 @default.
• W4385655145 hasConceptScore W4385655145C126322002 @default.
• W4385655145 hasConceptScore W4385655145C141071460 @default.
• W4385655145 hasConceptScore W4385655145C142724271 @default.
• W4385655145 hasConceptScore W4385655145C159654299 @default.
• W4385655145 hasConceptScore W4385655145C203014093 @default.
• W4385655145 hasConceptScore W4385655145C2777607188 @default.
• W4385655145 hasConceptScore W4385655145C2777633098 @default.
• W4385655145 hasConceptScore W4385655145C2779551797 @default.
• W4385655145 hasConceptScore W4385655145C2779951007 @default.
• W4385655145 hasConceptScore W4385655145C2908647359 @default.
• W4385655145 hasConceptScore W4385655145C36394416 @default.
• W4385655145 hasConceptScore W4385655145C535046627 @default.
• W4385655145 hasConceptScore W4385655145C71924100 @default.
• W4385655145 hasConceptScore W4385655145C90924648 @default.
• W4385655145 hasConceptScore W4385655145C99454951 @default.
• W4385655145 hasIssue "S3" @default.
• W4385655145 hasLocation W43856551451 @default.
• W4385655145 hasLocation W43856551452 @default.
• W4385655145 hasOpenAccess W4385655145 @default.
• W4385655145 hasPrimaryLocation W43856551451 @default.
• W4385655145 hasRelatedWork W158099351 @default.
• W4385655145 hasRelatedWork W2024812753 @default.
• W4385655145 hasRelatedWork W2025519321 @default.
• W4385655145 hasRelatedWork W2036851608 @default.
• W4385655145 hasRelatedWork W2056499894 @default.
• W4385655145 hasRelatedWork W2060301619 @default.
• W4385655145 hasRelatedWork W2155681756 @default.
• W4385655145 hasRelatedWork W2522056109 @default.
• W4385655145 hasRelatedWork W2892264640 @default.
• W4385655145 hasRelatedWork W2184270029 @default.
• W4385655145 hasVolume "7" @default.
• W4385655145 isParatext "false" @default.
• W4385655145 isRetracted "false" @default.
• W4385655145 workType "article" @default.